CN108026083B - 作为因子xia抑制剂的二酰胺大环 - Google Patents

作为因子xia抑制剂的二酰胺大环 Download PDF

Info

Publication number
CN108026083B
CN108026083B CN201680048685.4A CN201680048685A CN108026083B CN 108026083 B CN108026083 B CN 108026083B CN 201680048685 A CN201680048685 A CN 201680048685A CN 108026083 B CN108026083 B CN 108026083B
Authority
CN
China
Prior art keywords
substituted
alkyl
chloro
independently selected
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680048685.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108026083A (zh
Inventor
L.M.史密斯二世
D.J.P.平托
J.R.科特
W.R.尤因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN108026083A publication Critical patent/CN108026083A/zh
Application granted granted Critical
Publication of CN108026083B publication Critical patent/CN108026083B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680048685.4A 2015-06-19 2016-06-16 作为因子xia抑制剂的二酰胺大环 Active CN108026083B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181875P 2015-06-19 2015-06-19
US62/181875 2015-06-19
PCT/US2016/037823 WO2016205482A1 (en) 2015-06-19 2016-06-16 Diamide macrocycles as factor xia inhibitors

Publications (2)

Publication Number Publication Date
CN108026083A CN108026083A (zh) 2018-05-11
CN108026083B true CN108026083B (zh) 2021-08-27

Family

ID=56204067

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680048685.4A Active CN108026083B (zh) 2015-06-19 2016-06-16 作为因子xia抑制剂的二酰胺大环

Country Status (6)

Country Link
US (1) US10160750B2 (https=)
EP (1) EP3310777B1 (https=)
JP (1) JP6742348B2 (https=)
CN (1) CN108026083B (https=)
ES (1) ES2762987T3 (https=)
WO (1) WO2016205482A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2760821T3 (https=) 2014-01-31 2018-03-10
CN116987080A (zh) 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
WO2016205482A1 (en) 2015-06-19 2016-12-22 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
US10287288B2 (en) 2015-07-29 2019-05-14 Bristol-Myers Squibb Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties
ES2871111T3 (es) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
KR20180117156A (ko) 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클
JP2022513919A (ja) * 2018-12-17 2022-02-09 バイエル・アクチエンゲゼルシヤフト 血栓性または血小板塞栓性疾患および/または血栓性または血小板塞栓性合併症の治療および/または予防のための置換オキソピリジン誘導体
WO2021110076A1 (zh) * 2019-12-04 2021-06-10 深圳信立泰药业股份有限公司 草酰胺类衍生物、其制备方法及其在医药上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022814A1 (en) * 2011-08-05 2013-02-14 Bristol-Myers Squibb Company Cyclic p1 linkers as factor xia inhibitors
WO2014022767A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
CA2461202C (en) 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006076575A2 (en) 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
WO2006089005A2 (en) 2005-02-17 2006-08-24 Bristol-Myers Squibb Company Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
EP1981854B1 (en) 2005-12-14 2011-06-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007070816A2 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors
AR058380A1 (es) * 2005-12-23 2008-01-30 Bristol Myers Squibb Co Inhibidores del factor viia macrociclicos utiles como anticoagulantes
CN101605779B (zh) 2006-12-15 2013-11-20 百时美施贵宝公司 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物
CA2676933C (en) 2007-02-28 2015-09-29 Leo Pharma A/S Novel phosphodiesterase inhibitors
AR067329A1 (es) 2007-06-13 2009-10-07 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
US8324199B2 (en) 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
FR2944014A1 (fr) 2009-04-06 2010-10-08 Univ Grenoble 1 Peptides cycliques a activite antiparasitaire
ES2674745T3 (es) 2010-02-11 2018-07-03 Bristol-Myers Squibb Company Macrociclos como inhibidores del factor XIa
EP2603080A4 (en) 2010-08-12 2014-01-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
KR101937514B1 (ko) 2011-10-14 2019-01-10 브리스톨-마이어스 스큅 컴퍼니 인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물
KR20150038369A (ko) 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
TR201807316T4 (tr) 2012-10-12 2018-06-21 Bristol Myers Squibb Co Bir faktör XIa inhibitörünün kristalli formları.
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
NO2760821T3 (https=) 2014-01-31 2018-03-10
CN116987080A (zh) 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
NO2721243T3 (https=) 2014-10-01 2018-10-20
WO2016205482A1 (en) 2015-06-19 2016-12-22 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
ES2871111T3 (es) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
US10287288B2 (en) 2015-07-29 2019-05-14 Bristol-Myers Squibb Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties
ES2754599T3 (es) 2015-08-05 2020-04-20 Bristol Myers Squibb Co Nuevos inhibidores de FXIa derivados de glicina sustituidos
KR20180117156A (ko) 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022814A1 (en) * 2011-08-05 2013-02-14 Bristol-Myers Squibb Company Cyclic p1 linkers as factor xia inhibitors
WO2014022767A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS

Also Published As

Publication number Publication date
WO2016205482A1 (en) 2016-12-22
ES2762987T3 (es) 2020-05-26
US10160750B2 (en) 2018-12-25
EP3310777A1 (en) 2018-04-25
JP6742348B2 (ja) 2020-08-19
JP2018517753A (ja) 2018-07-05
CN108026083A (zh) 2018-05-11
EP3310777B1 (en) 2019-10-09
US20180141932A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
CN110734435B (zh) 作为因子xia抑制剂的嘧啶酮
US10273236B2 (en) Macrocyclic factor XIa inhibitors bearing heterocyclic groups
CN108137549B (zh) 取代的甘氨酸衍生的fxia抑制剂
CN108026083B (zh) 作为因子xia抑制剂的二酰胺大环
CN107849026B (zh) 携带烷基或环烷基p2′部分的因子xia大环抑制剂
CN114874222B (zh) 携带非芳族p2,基团的因子xia新大环
HK40023053B (en) Pyrimidinones as factor xia inhibitors
HK40023053A (en) Pyrimidinones as factor xia inhibitors
HK40053570B (en) Pyrimidinones as factor xia inhibitors
HK40053570A (en) Pyrimidinones as factor xia inhibitors
BR112017006702B1 (pt) Pirimidinonas inibidoras de fator xia, composição farmacêutica e seu uso
HK1227032B (en) Pyrimidinones as factor xia inhibitors
HK1227032A1 (en) Pyrimidinones as factor xia inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant